• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).致编辑的信：关于晚期胆管癌的分子靶向维持治疗与标准治疗：一项国际、随机、对照、开放标签的III期伞式试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Jul 15;10(8):105535. doi: 10.1016/j.esmoop.2025.105535.
2
Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).对关于以下内容的信件评论的回复：晚期胆管癌的分子靶向维持治疗与标准治疗的比较：一项国际、随机、对照、开放标签的III期伞式试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Jul 18;10(8):105536. doi: 10.1016/j.esmoop.2025.105536.
3
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).晚期胆管癌的分子靶向维持治疗与标准治疗对比：一项国际、随机、对照、开放标签的III期伞形试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Apr 9;10(5):104540. doi: 10.1016/j.esmoop.2025.104540.
4
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.贝伐珠单抗联合厄洛替尼作为化疗敏感晚期胆囊癌和胆管癌的维持治疗（BEER BTC）：一项多中心、开放标签、随机、II 期临床试验。
J Clin Oncol. 2024 Sep 20;42(27):3218-3227. doi: 10.1200/JCO.23.02420. Epub 2024 Aug 5.
5
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).曲妥珠单抗多卡霉素用于经治的人表皮生长因子受体2阳性晚期或转移性乳腺癌：一项开放标签、随机、III期试验（郁金香试验）
J Clin Oncol. 2025 Feb 10;43(5):513-523. doi: 10.1200/JCO.24.00529. Epub 2024 Oct 23.
6
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
7
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.基于吉西他滨的晚期胆管癌化疗
Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2.
8
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
9
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.
10
Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.温阳通腑法在转移性结肠癌维持治疗中的疗效与安全性
World J Clin Oncol. 2025 Jun 24;16(6):105175. doi: 10.5306/wjco.v16.i6.105175.

本文引用的文献

1
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).晚期胆管癌的分子靶向维持治疗与标准治疗对比：一项国际、随机、对照、开放标签的III期伞形试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Apr 9;10(5):104540. doi: 10.1016/j.esmoop.2025.104540.
2
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.用于治疗FGFR2重排型肝内胆管癌的futibatinib
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
3
Design and analysis of umbrella trials: Where do we stand?伞形试验的设计与分析：我们目前的进展如何？
Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022.
4
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring / Aberrations: A Phase I Dose-Expansion Study.富替替尼，一种不可逆的 FGFR1-4 抑制剂，用于携带/突变的晚期实体瘤患者：一项 I 期剂量扩展研究。
Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22.

Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

作者信息

Zhou F, Chen W, Ruan L

机构信息

Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi Province, China.

Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi Province, China.

出版信息

ESMO Open. 2025 Jul 15;10(8):105535. doi: 10.1016/j.esmoop.2025.105535.

DOI:10.1016/j.esmoop.2025.105535
PMID:40669093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281191/
Abstract
摘要